gant-61 and Inflammatory-Breast-Neoplasms

gant-61 has been researched along with Inflammatory-Breast-Neoplasms* in 1 studies

Other Studies

1 other study(ies) available for gant-61 and Inflammatory-Breast-Neoplasms

ArticleYear
Pharmacological targeting of GLI1 inhibits proliferation, tumor emboli formation and in vivo tumor growth of inflammatory breast cancer cells.
    Cancer letters, 2017, 12-28, Volume: 411

    Activation of the Hedgehog (Hh) pathway effector GLI1 is linked to tumorigenesis and invasiveness in a number of cancers, with targeting of GLI1 by small molecule antagonists shown to be effective. We profiled a collection of GLI antagonists possessing distinct mechanisms of action for efficacy in phenotypic models of inflammatory and non-inflammatory breast cancer (IBC and non-IBC) that we showed expressed varying levels of Hh pathway mediators. Compounds GANT61, HPI-1, and JK184 decreased cell proliferation, inhibited GLI1 mRNA expression and decreased the number of colonies formed in TN-IBC (SUM149) and TNBC (MDA-MB-231 and SUM159) cell lines. In addition, GANT61 and JK184 significantly down-regulated GLI1 targets that regulate cell cycle (cyclin D and E) and apoptosis (Bcl2). GANT61 reduced SUM149 spheroid growth and emboli formation, and in orthotopic SUM149 tumor models significantly decreased tumor growth. We successfully utilized phenotypic profiling to identify a subset of GLI1 antagonists that were prioritized for testing in in vivo models. Our results indicated that GLI1 activation in TN-IBC as in TNBC, plays a vital role in promoting cell proliferation, motility, tumor growth, and formation of tumor emboli.

    Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Heterocyclic Compounds, 2-Ring; Humans; Inflammatory Breast Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Molecular Targeted Therapy; Pyridines; Pyrimidines; Signal Transduction; Thiazoles; Xenograft Model Antitumor Assays; Zinc Finger Protein GLI1

2017